



BioFacilities News / Updates

Free, bi-monthly newsletter; tracking news/trends in the biologics industry; 100s of sources filtered by our analysts; 20+ years' experience

BioPlan Publications

[NEW! 14th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production](#)

Our most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production.



SPECIAL - FREE 2017 SUMMARY: Top 15 Trends in Biopharmaceutical Manufacturing, 2017
[Click Here](#)

New Bio-Facilities Planned

GE is investing €150M in a new manufacturing facility at Loughbeg, Ringaskiddy, Co. Cork, Ireland. Four KuBio modular facilities will be run by GE for 4 different clients. *Source: American Pharmaceutical Review, Sept. 19, 2016*

Novartis is investing \$100M to expand its monoclonal antibodies manufacturing facility, Novartis Pharma S.A.S. Biotechnology Center, in Huningue, France, including new bioreactors and a second DSP line. *Source: Pharmaceutical Services Directory, Aug. 17, 2016*

Novo Nordisk is expanding its Kalundborg, Denmark, manufacturing facility, already the world's largest insulin manufacturing plant, producing 50% of the world's supply. About \$60M will be spent on upgrades. *Source: FiercePharma, July 5, 2016*

Cipla BioTec (India) is constructing an \$89M biosimilars manufacturing facility in Durban, South Africa, and is expected to come online in later 2018. *Source: Pharmaceutical Manufacturing, July 11, 2016*

Merck KGaA (MilliporeSigma) is constructing a 280,000-sq. ft., \$115M life sciences R&D center in Burlington, Massachusetts, USA. *Source: Boston Globe, July 19, 2016*

Catalent (Madison, WI) is doubling its bioprocessing capacity with the addition of 2 x 2,000 L bioreactors. *Source: BioPharma-Reporter.com, Aug. 30, 2016*

BiolInvent (Lund, Sweden) is expanding its microbial manufacturing capacity, including adding a 1,000 L single-use bioreactor suite. *Source: BioPharma-Reporter.com, Sept. 6, 2016]*

Alexion is investing €100M to expand its fill-finish facility in Athlone, Ireland. *Source: FORA, July 7, 2016*

Alnylam is building a \$200M RNAi manufacturing facility in Norton, Massachusetts, USA, with engineering support from Jacobs Engineering. *Source: In-PharmaTechnologist.com; Aug. 8, 2016*

Vetter is building a sterile injectables manufacturing facility in Des Plaines, Illinois, USA; investing \$320M to create a 1.1M sq. ft. facility. *Source: Contract Pharma, July 14, 2016*

Fresenius Kabi is investing \$250M on a new generic sterile injectables facility in Melrose Park, Illinois, USA. *Source: In-PharmaTechnologist.com, Aug. 18, 2016*

Greenland Holdings, a Chinese govt-backed co., is investing >\$1B in a biotech industrial park in South San Francisco, California, USA, with smaller peers - Agile Group, Ping An Trust and Poly Sino Capital. *Source: Reuters, Aug. 18, 2016*

New Facilities

Rentschler Biotechnologie opened a facility in Laupheim, Germany, anchored by 2 x 3,000 L stainless steel bioreactors for clinical products manufacturing, including plans to hire 200 staff. *Source: Biopharma-reporter.com; Sept. 16, 2016*

Lonza is now adding an additional 150,000 sq. ft. to a recently completed 100,000 sq. ft. gene/cellular therapies manufacturing facility in Pearland, Texas, USA; and Lonza has licensed a popular adeno-associated virus (AAV) gene therapy vector platform from Massachusetts Eye and Ear Hospital. *Source: Biopharma-reporter.com; Sept. 30, 2016*

Kyowa Hakko Kirin completed construction of a \$70M mAb manufacturing facility, HB6, in Takasaki, Japan, anchored by a 12,000 L bioreactor. *Source: Biopharma-reporter.com; Aug. 5, 2016*

Avacta opened two facilities in Wetherby and Cambridge, UK, to support development of Affimer E. coli-expressed antibodies. *Source: Biopharma-Reporter.com; Aug. 17, 2016*

The Syngene Amgen Research and Development Center (SARC), an R&D center to be operated for Amgen, opened in Bangalore, India. *Source: Pharmaceutical Outsourcing, Sept. 6, 2016*

Kite Pharma (El Segundo, CA) opened a 43,500 sq. ft. gene/cellular therapies facility including for manufacturing of upcoming autologous CAR-T therapies, capable of 4-5,000 therapies/year. Source: BioPharmaDive, Aug. 9, 2016

GE opened a new \$7.4M bioprocessing training facility in Songdo, Korea. Source: Various, 2016

SGS opened a new facility in Wiesbaden, Germany, exclusively to offer extractables and leachables testing services. Source: *Pharmaceutical Outsourcing*, Sept. 12, 2016

BioINNOVATIONS

Ajinomoto Althea Inc. received a U.S. patent covering methods to crystallize monoclonal antibodies for scale up and cGMP manufacturing for therapeutic use. Source: *PRNewswire*, May 17, 2016

Shire, after completion of its \$320M acquisition of Baxalta, abandoned its development of biosimilar products, and is now concentrating solely on rare disease therapeutics. Source: *BioPortfolio*; Sept. 26, 2016

Merck KGaA (MilliporeSigma) launched a new Centinel CHO gene editing technology allowing cells to be resistant to minute virus of mice (MVM) infection. Source: *American Pharmaceutical Review*, Sept. 8, 2016

GE formed a collaboration with Sealed Air Corp. for development of single-use plastic films. Source: *Biopharm Intl.*, Sept. 1, 2016

Wrap-Up BioNews

Asahi Glass (AGC; Tokyo, Japan) acquired Biomeva GmbH (Heidelberg, Germany), a CMO specializing in microbial manufacturing. Source: *ThePharmaletter*, Sept. 19, 2016

GE acquired Biosafe Group, a cellular therapies supplier and launched the Sefia line of cellular therapy manufacturing products. Source: *GE PR*, Sept. 30, 2016

Pfizer's vaccine manufacturing facilities in Pearl River, New York, USA, in use for many decades, are finally being decommissioned. Source: *FiercePharma*, Aug. 2, 2016

MEDIA AND ORGANIZATIONAL PARTNERS



Comments/Suggestions/Resources

Questions? Comments? Let us know. Our interest is to provide you the highest value information and service available.

If you require custom research, BioPlan Associates, Inc., has been delivering actionable market data and customer analysis to the biopharma and life sciences industries for almost 30 years.

Contact us for a free evaluation and research proposal.

BioPlan Associates, Inc. | 1-301-921-5979 | info@bioplanassociates.com | www.bioplanassociates.com

STAY CONNECTED:



BioFacilities Newsletter
Issue: Vol. 6, No. 2
Jun/July 2017